PNC Financial Services Group’s Hepion Pharmaceuticals HEPA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-156
| Closed | -$67 | – | 4980 |
|
|
2025
Q1 | $67 | Buy |
156
+2
| +1% | +$19 | ﹤0.01% | 4837 |
|
|
2024
Q4 | $3.63K | Hold |
154
| – | – | ﹤0.01% | 4124 |
|
|
2024
Q3 | $5.17K | Hold |
154
| – | – | ﹤0.01% | 4029 |
|
|
2024
Q2 | $7.88K | Sell |
154
-4
| -3% | -$295 | ﹤0.01% | 3854 |
|
|
2024
Q1 | $19.6K | Buy |
158
+100
| +172% | +$11.5K | ﹤0.01% | 3457 |
|
|
2023
Q4 | $9.33K | Hold |
58
| – | – | ﹤0.01% | 3747 |
|
|
2023
Q3 | $14.4K | Hold |
58
| – | – | ﹤0.01% | 3603 |
|
|
2023
Q2 | $30.2K | Hold |
58
| – | – | ﹤0.01% | 3337 |
|
|
2023
Q1 | $44.6K | Hold |
58
| – | – | ﹤0.01% | 3062 |
|
|
2022
Q4 | $17.3K | Hold |
58
| – | – | ﹤0.01% | 3541 |
|
|
2022
Q3 | $29K | Hold |
58
| – | – | ﹤0.01% | 3266 |
|
|
2022
Q2 | $33K | Hold |
58
| – | – | ﹤0.01% | 3233 |
|
|
2022
Q1 | $74K | Hold |
58
| – | – | ﹤0.01% | 2881 |
|
|
2021
Q4 | $66K | Buy |
58
+19
| +49% | +$26K | ﹤0.01% | 2947 |
|
|
2021
Q3 | $60K | Buy |
+39
| New | +$62.4K | ﹤0.01% | 2957 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 4036 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 4043 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 4718 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 4719 |
|
Other funds holding HEPA
PNC Financial Services Group's HEPA Position: Q2 2025 in Review
PNC Financial Services Group sold out of Hepion Pharmaceuticals (HEPA) in Q2 2025, closing a stake of 156 shares — an estimated $67 sold.
PNC Financial Services Group first reported a position in HEPA in Q3 2021 and held it in 15 quarters. The position peaked at $74K in Q1 2022. 4 funds tracked by Wall St. Rank hold HEPA as of Q2 2025.
- PNC Financial Services Group reported no remaining Hepion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- PNC Financial Services Group sold 156 Hepion Pharmaceuticals shares in Q2 2025, an estimated $67.
- PNC Financial Services Group first reported a position in Hepion Pharmaceuticals in Q3 2021 and held it in 15 quarters.
- PNC Financial Services Group's Hepion Pharmaceuticals position peaked at $74K in Q1 2022.
- 4 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2025.
Based on PNC Financial Services Group's 13F filing for Q2 2025, filed 8 Aug 2025.